Compare MLP & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | CERS |
|---|---|---|
| Founded | 1909 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.2M | 276.0M |
| IPO Year | 2010 | 1996 |
| Metric | MLP | CERS |
|---|---|---|
| Price | $16.09 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | $11,565,000.00 | ★ $51,326,000.00 |
| Revenue This Year | N/A | $20.00 |
| Revenue Next Year | N/A | $9.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.96 | ★ 30.68 |
| 52 Week Low | $13.84 | $1.12 |
| 52 Week High | $20.34 | $2.96 |
| Indicator | MLP | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 32.71 |
| Support Level | $15.75 | $1.27 |
| Resistance Level | $17.43 | $2.26 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 6.25 | 5.24 |
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.